Neoprobe Corp. (OTC:NEOP) shareholders took a bath in the second quarter, largely because of one-time charges related to converting their company’s debt to preferred equity.
Navidea Biopharmaceuticals
Neoprobe seeks NYSE listing
Neoprobe Inc. (OTC:NEOP) has applied for listing on the New York Stock Exchange.
The move would make the Dublin, Ohio-based company more attractive to institutional investors and provide more liquidity for existing investors, according to a press release. CEO David Bupp said it could take “a number of weeks” before Neoprobe receives approval for the listing.
Neoprobe: Q2 revenues rise 45 percent
By Mary Vanac
Medical device maker and drug developer Neoprobe Corp. (OTC:NEOP) expects to announce in early August that its revenue growth accelerated 45 percent in the second quarter from a year ago.
Neoprobe nominates two for board
Drug and device firm Neoprobe Inc. has nominated two new directors who will stand for election at the company’s annual shareholder meeting in July.